Substituted pyrindinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto

Abstract

The present invention relates to certain substituted pyridinyl and pyrimidinyl derivatives of Fomula (Ia) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.

1 . A compound selected from compounds of the following Formula:  
       
         
           
           
               
               
           
         
         and pharmaceutically acceptable salts, solvates, and hydrates thereof.  
       
     
     
         2 . A pharmaceutical composition comprising a compound according to  claim 1  and a pharmaceutically acceptable carrier.  
     
     
         3 . A method of treating a metabolic-related disorder in an individual comprising administering to said individual in need of such treatment a therapeutically effective amount of a compound according to  claim 1 .  
     
     
         4 . The method according to  claim 3 , wherein said metabolic-related disorder is selected from the group consisting of type I diabetes, type II diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia and syndrome X.  
     
     
         5 . The method according to  claim 3 , wherein said metabolic-related disorder is type II diabetes.  
     
     
         6 . The method according to  claim 3 , wherein said metabolic-related disorder is hyperglycemia.  
     
     
         7 . The method according to  claim 3 , wherein said metabolic-related disorder is hyperlipidemia.  
     
     
         8 . The method according to  claim 3 , wherein said metabolic-related disorder is hypertriglyceridemia.  
     
     
         9 . The method according to  claim 3 , wherein said metabolic-related disorder is type I diabetes.  
     
     
         10 . The method according to  claim 3 , wherein said metabolic-related disorder is dyslipidemia.  
     
     
         11 . The method according to  claim 3 , wherein said metabolic-related disorder is syndrome X.  
     
     
         12 . The method according to  claim 3 , wherein said individual is a human.  
     
     
         13 . The method of treating obesity in an individual comprising administering to said individual in need of treatment a therapeutically effective amount of a compound according to  claim 1 .  
     
     
         14 . A method of decreasing food intake of an individual comprising administering to said individual in need thereof a therapeutically effective amount of a compound according to  claim 1 .  
     
     
         15 . A method of inducing satiety in an individual comprising administering to said individual in need thereof a therapeutically effective amount of a compound according to  claim 1 .  
     
     
         16 . A method of controlling or decreasing weight gain of an individual comprising administering to said individual in need thereof a therapeutically effective amount of a compound according to  claim 1 .  
     
     
         17 . The method according to  claim 16 , wherein said individual is a human.  
     
     
         18 . The method according to  claim 17 , wherein said human has a body mass index of about 18.5 to about 45.  
     
     
         19 . The method of producing a pharmaceutical composition comprising admixing a compound according to  claim 1  and a pharmaceutically acceptable carrier.